> Pharmaceutical Litigation > Omontys
Omontys is an injection given to treat anemia in kidney dialysis patients that has been linked to severe hypersensitivity reactions, including life-threatening anaphylaxis.
Omontys is an erythropoiesis-stimulating agent (ESA) given to aid in the formation of red blood cells. The Food and Drug Administration approved Omontys for use in adult dialysis patients with chronic kidney disease in March 2012. The first adverse event report citing anaphylaxis reached the FDA on Aug. 14, 2012, and more continued to file in as use of the drug expanded. By Oct. 31, 2012, Omontys carried a label warning about hypersensitivity reactions. Omontys was finally recalled on Feb. 22, 2013. By that time, 98 adverse events were reported, and the drug was suspected in several deaths.
Omontys was used in over 25,000 patients, according to the FDA. So far approximately 50 cases of hypersensitivity have been reported to the FDA, with a third of those being serious reactions including anaphylaxis. Fatal reactions are known to have occurred following the first dose of Omontys in 5 patients. These numbers reflect only the reports sent to the FDA and, therefore, the minimum number of victims injured by Omontys.
If you or a loved one experienced a hypersensitivity reaction, including anaphylaxis, upon receiving treatment with Omontys, contact the Law Offices of Brian D. Witzer by calling (888) WITZER-6 for a free, no-obligation consultation.
You deserve compensation for your physical, emotional and financial suffering. We are dedicated to seeking justice for those harmed by Omontys.